This subgroup analysis of SUSTAIN-3 (n=96) studies patients with treatment-resistant depression (TRD) who received a second induction and maintenance treatment with esketamine nasal spray (ESK) plus oral antidepressant (AD) after a relapse in SUSTAIN-1.
- Published
- Journal
- CNS Drugs
- Authors
- Castro, M., Wilkinson, S. T., Al Jurdi, R. K., Petrillo, M. P.z, Sun, L., Zaki, N., Borentain, S., Turkoz, I., Brown, B., Cabrera, P., Fu, D. J.